Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Insights for the Multidisciplinary Team

BTK Inhibitors in B-cell Malignancies Program Image
Hear the latest data from lymphoma experts on the use of BTK inhibitors for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies in this live, case-based interactive local event, and then download the meeting slideset for use in your own presentations.
Christopher R. Flowers, MD, MS
Andrew D. Zelenetz, MD, PhD

Downloadable Slideset

These downloadable slides from our live meeting series on BTK inhibitors review the current clinical rationale and most recent data on the use of ibrutinib and acalabrutinib for patients with MCL, CLL, or WM.

Christopher R. Flowers, MD, MS Andrew D. Zelenetz, MD, PhD Released: September 10, 2018
Jointly provided by the Purdue University and Clinical Care Options, LLC
Purdue University Logo

Accreditation: Dawn Sinclair, Purdue University sinclaid@purdue.edu
Certificates/Credits: Heather Holley, Purdue University hholley@purdue.edu

This activity is supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?